Neuropilin 1 antibody (FITC)

Catalog No. ABIN2661386

Product Details anti-Neuropilin 1 Antibody (FITC)

Target: Neuropilin 1 (NRP1)

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This Neuropilin 1 antibody is conjugated to FITC

Application: Flow Cytometry (FACS), Intracellular Flow Cytometry (ICFC)

Purification: The antibody was purified by affinity chromatography and conjugated with FITC under optimal conditions. The solution is free of unconjugated FITC and unconjugated antibody.

Clone: 12C2

Isotype: IgG2a kappa

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide and 0.2 % (w/v) BSA .

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling Advice: Protect from prolonged exposure to light. Do not freeze.

Storage: 4 °C

Storage Comment: The antibody solution should be stored undiluted between 2°C and 8°C.

Target Details for Neuropilin 1

Target: Neuropilin 1 (NRP1)

Alternative Name: CD304 (NRP1 Products)

Synonyms: NRP1 antibody, cd304 antibody, neuropilin antibody, np-1 antibody, npn-1 antibody, nrp antibody, nrp-1 antibody, vegf165r antibody, BDCA4 antibody, CD304 antibody, NP1 antibody, NRP antibody, VEGF165R antibody, C530029I03 antibody, NP-1 antibody, NPN-1 antibody, Npn1 antibody, Nrp antibody, neuropilin 1 antibody, neuropilin 1 L homeolog antibody, NRP1 antibody, nrp1 antibody, Nrp1 antibody, nrp1.L antibody

Background: CD304, also known as neuropilin-1, BDCA-4 and VEGF165R, is a 140 kD type I transmembrane protein. Its extracellular region contains 2 CUB, 2 FV/FVIII, and one MAM domain, a soluble isoform is produced by alternative mRNA splicing. CD304 is involved in angiogenesis, neural development, and tumor metastasis. It's expressed by plasmacytoid dendritic cells, thymocytes, neurons, endothelium, and a subset of TFH cells. CD304 is also expressed in several carcinomas, and a high expression of this molecule in prostate cancer correlates with a poor prognosis.

Pathways: Regulation of Cell Size, Signaling Events mediated by VEGFR1 and VEGFR2, Smooth Muscle Cell Migration, Platelet-derived growth Factor Receptor Signaling, VEGFR1 Specific Signals